文献速递前列腺癌

前列腺癌的流行病学、危险因素与预防

Epidemiology, Risk Factors, and Prevention of Prostate Cancer.
PubMed 文献 · Eur Urol · 2026-10-23

家族史、胚系致病变异和 ancestry 是危险因素,尚无单一营养素或补充剂被证实可降低发病率。

要点

  • 吸烟和肥胖与前列腺癌特异性死亡相关,体力活动和植物性/地中海饮食与较低进展风险相关。

核心结论

  • 全球前列腺癌负担因人口增长和老龄化预计到2050年大幅上升,尤其在低中收入地区。
  • 家族史、胚系致病变异和ancestry是前列腺癌危险因素,但证据不足以支持任何特定预防干预。
  • 吸烟、饮食和体力活动可能改变进展或死亡风险。

研究设计与样本

  • 基于GLOBOCAN 2024数据库估计185个国家2024年发病和死亡数据,并假设年龄别率不变预测至2050年。
  • 结合叙述性文献综述总结危险因素和预防措施。

主要发现

  • 2024年前列腺癌死亡42万例(7.5/10万),加勒比地区死亡率ASR最高(29),南中亚最低(3.4)。
  • PSA筛查影响发病率和地理差异;非洲与欧洲裔男性差异反映肿瘤生物学和医疗可及性不平等。
  • 无单一营养素或补充剂被证实降低前列腺癌发病率;吸烟和肥胖与前列腺癌特异性死亡相关。

关键数值与推荐

  • 北美发病率ASR最高(81),南中亚最低(7.2);加勒比死亡率ASR最高(29),南中亚最低(3.4)。

临床怎么用

  • 临床应关注家族史、胚系致病变异和ancestry等高危因素进行风险分层。
  • 鼓励戒烟、控制体重、增加体力活动和植物性/地中海饮食以可能降低进展或死亡风险。
  • 知晓PSA筛查对发病率和地理差异的影响,并注意医疗可及性差异。

局限性

  • 预测基于2024年年龄别发病率与死亡率不变的假设,未考虑危险因素和治疗变化。
  • 证据来自叙述性综述,非系统评价。
  • 低中收入地区数据可能存在登记不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There are substantial regional differences in prostate cancer (PCa) epidemiology reflecting differences in risk factors, screening, management, and access to care. OBJECTIVE: To assess geographical differences and temporal trends in PCa incidence and mortality and PCa risk factors. EVIDENCE ACQUISITION: Estimated incidence and mortality data for the year 2024 and projections to 2050 based on the assumption that 2024 age-specific incidence and mortality rates remain unchanged (not accounting for changes in risk factors and/or treatments) in 185 countries were derived from the International Agency for Research on Cancer's GLOBOCAN 2024 database. A narrative review of the literature summarized risk factors and preventive measures. EVIDENCE SYNTHESIS: Worldwide, 1.55 million new PCa cases were estimated in 2024, with an age-standardized rate (ASR) for incidence of 29 per 100 000. Northern America had the highest all-age incidence ASR (81), and South-Central Asia the lowest (7.2). PCa caused an estimated 420 000 deaths (7.5 per 100 000), with the highest mortality ASRs in the Caribbean (29) and the lowest in South-Central Asia (3.4). By 2050, new cases are projected to be 2.88 million (+86%) and deaths 924 000 (+120%), with the largest relative increases in Africa (+156%). Prostate-specific antigen-based screening influences both incidence and geographic variation. Family history, germ line pathogenic variants, polygenic risk scores, and ancestry are risk factors. Disparities in men of African versus European ancestry reflect both tumor biology and unequal access to care, with mortality gaps narrowing in equal-access health systems. No single nutrient or supplement has been shown to reduce PCa incidence. Cigarette smoking and obesity are associated with PCa-specific mortality, whereas physical activity and plant-based or Mediterranean dietary patterns are associated with a lower risk of disease progression. CONCLUSIONS: The global burden of PCa because of population increase and aging is projected to rise substantially by 2050, particularly in low- and middle-income regions. Family history, germ line pathogenic variants, and ancestry are risk factors for PCa. Evidence remains insufficient to support any specific preventive intervention, although smoking, diet, and physical activity may modify risk of progression or mortality.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gandaglia G, Weiner AB, Briganti A, et al. Epidemiology, Risk Factors, and Prevention of Prostate Cancer. Eur Urol. 2026. PMID: 42919739. doi:10.1016/j.eururo.2026.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。